Oncotype DX®

Is Testing Right for Me? I Have My Test Results

Oncotype DX®

References

  1. Paik S, Shak S, Tang G, et al. A multi-gene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26.
  2. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-34.
  3. Habel LA, Shak S, Jacobs M, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8(3):R25.
  4. Lo SS, Norton J, Mumby PB et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2007;25 (June 20 Supplement):577.
  5. Oratz R, Paul D, Cohn AL, Sedlacek SM. Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract. 2007;3(4):182-8.
  6. Asad J, Jacobson AF, Estabrook A, et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg. 2008;196:527-9.
  7. Mumby PB, Lo SS, Norton J, et al. Prospective multi-center study of the impact of the 21-gene recurrence score assay on patient satisfaction, anxiety and decisional conflict for adjuvant breast cancer treatment selection. Abstract #1092 presented at the 2007 San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-17, 2007.
  8. SEER – Surveillance Epidemiology and End-Result Program of the National Cancer Institute. Version 6.4.4. Available at http://seer.cancer.gov/seerstat. Accessed July 13, 2011.
  9. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Breast Cancer. V.2.2011. Available at nccn.org . Accessed July 13, 2011.
  10. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol. 2007;25(33):5287-312. Available at: http://jco.ascopubs.org/cgi/content/full/25/33/5287. Accessed July 13, 2011.
  11. Eastern Cooperative Oncology Group. Patient Education Materials Available for TAILORx. Available at: http://www.ecog.org/general/tailorx.html. Accessed July 11, 2011.
  12. Southwestern Oncology Group (SWOG). Study protocol abstract: A phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone-responsive and her2-negative breast cancer according to Recurrence Score (RS). Available at swog.org. Accessed July 13, 2011.